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Abstract
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Glioblastoma is a fatal brain cancer with low median and yearly survival rates. The standard of
care for treating glioblastoma is gross total resection (GTR) coupled with the Stupp protocol, but
various factors influence the interventions undertaken and survival achieved. As health disparities
exist in rural areas, survival in these areas need to be assessed in order to understand which factors
detract from the successes of these standard medical interventions. We retrospectively determined
the impact of age of diagnosis, number of lesions, the molecular marker O6-methylguanine
methyltransferase (MGMT), extent of surgery, and completion of the Stupp protocol on survival
among patients treated at West Virginia University Hospitals. We found that an age of diagnosis
under 60 years, having the MGMT gene methylated, having a unifocal tumor, receiving GTR,
adhering to the Stupp protocol, and undergoing a treatment course of GTR followed by the Stupp
protocol significantly increased survival. Lastly, we compared our findings to a pre-Stupp study
done in West Virginia in 1996. This comparison showed that although overall median survival has
not increased, all interventions involving GTR have resulted in a significantly higher survival. We
conclude that we can serve our patient population by offering GTR to all adult glioblastoma
patients when no contraindications exist and ensuring that patients follow the Stupp protocol.
After discharge, the Stupp protocol may not be followed/completed for a variety of reasons. In the
future, we aim to assess these reasons and analyze other significant interventional and
socioeconomic factors which influence survival.
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Glioblastoma, an aggressive glial tumor, is the most prevalent brain tumor in adults and
usually occurs in middle-aged patients. On imaging, these tumors appear as contrast
enhancing masses, sometimes with a butterfly pattern that can often extend across the corpus
callosum. Microscopically, the tumors have central areas of necrosis and hemorrhage
surrounded by pseudopalisading cells. Median survival for adults with glioblastoma who
undergo appropriate therapy has been reported to be 14.6 months while 2-year survival is
26.5%27; patients surviving beyond 36 months are known as long-term survivors. Prognostic
indicators of increased survival time are young age, having a single tumor, O6methylguanine methyltransferase (MGMT) methylation, gross total resection (GTR) of the
presenting lesion, and post-operative completion of the Stupp protocol.

Author Manuscript

The Stupp protocol calls for the use of 60Gy radiotherapy concurrently with temozolomide
(TMZ) over 6 weeks after tumor resection, followed by six 28-day cycles of TMZ alone.
The success of this protocol is linked to MGMT methylation as MGMT expression causes
tumor resistance to alkylating chemotherapeutic agents such as TMZ and nitrosureas. When
this gene is silenced (methylated), the tumor’s DNA repair is impaired and chemotherapy
becomes more effective, especially when combined with radiation9. This observation that
the prognostic value of MGMT methylation is dependent on treatment modality builds upon
the Stupp findings27. MGMT methylation has also been linked to long-term survival26.
West Virginia, a mostly rural state5 in the Appalachian region which is medically
underserved and economically disadvantaged3, is known to have many negative health
outcome metrics. These include a high overall cancer prevalence relative to the U.S’
median12, as well as a high cancer mortality of 223.9/100000 people and high rates of
obesity (35.6%) and diabetes (14.5%)2. These statistics earned West Virginia ranks of 48,
47, and 49, relative to other states2. Furthermore, West Virginia also rates below the median
of the U.S. regarding the social determinants of health such as education and income2, which
have been identified as primary influences driving disparities in cancer morbidity and
mortality11. These statistics indicate that there are underlying sociodemographic issues that
detract from the benefit patients may otherwise experience from a medical intervention.
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The Appalachian region’s health disparities have impacted the cancer morbidity and
mortality for this population. Although cancer rates have declined in the U.S.25, this decline
has been lower in Appalachia31, with the incidence of cancer being higher in Appalachia
than the U.S. in general29. It has been shown that although mortality rates have decreased by
22% in the U.S in general from 1990–2001, rural Appalachia has only experienced a decline
of 12%30. Across the entire U.S, the incidence of cancer was shown to increase only in rural
Appalachia between 2007 and 201130.
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A pre-Stupp study by Jubilirer in 1996 at Charleston Area Medical Center (CAMC) in West
Virginia found that a younger age at diagnosis (<40) and radiotherapy (albeit of varying
doses) were the best predictors of survival in 138 patients16, a result which has been verified
by other studies8,18. However, due to both tumor (e.g. location) and patient characteristics
such as comorbidities, this approach is not always practical. The impact on survival of
implementing the Stupp protocol in an Appalachian hospital is unknown but could be
important in standardizing and optimizing treatment practices and delivery of care in West
Virginia and Appalachia in general, especially in light of the state’s poor health metrics. We
analyzed data from 243 glioblastoma patients from 2009-present to determine patient
demographics and survival, tumor characteristics, and courses of treatment. We then used
multivariate analyses to determine which combination of these factors yielded the greatest
survival in our patients. As our institution serves a mostly rural population with its own
health disparities, we hypothesized that our population would show an overall median
survival less than that shown by Stupp et al27 but that the reported indicators of increased
survival will also serve as good prognostic indicators in out patient population. This research
serves as a springboard for finding deficiencies in glioblastoma care and identifying ways to
ameliorate those deficiencies in economically disadvantaged rural communities.

Author Manuscript

Methods
Study Approval
This retrospective cohort study was approved by the WVU Office of Research Integrity and
Compliance.
Study Design
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The information for this study was gleaned from West Virginia University Hospital’s
(WVUH) electronic medical record as well as other hospitals’ records when needed. Our
data came from 243 living and deceased patients and consisted of 96 females (39.5%) and
147 males (60.5%) ranging between the ages of 20–88 at diagnosis. Only newly diagnosed
cases with a definitive pathologic diagnosis of glioblastoma were included. These diagnoses
were made by a neuro-pathologist who was at our institution for the entire period we
reviewed in this study. Most resections done at our institution (89%) were done by four
surgeons, whose techniques were tailored largely to the tumor’s location. Although all
surgeries used pre-operative imaging, post-operative imaging was not done in all cases. One
surgeon frequently used fluorescein staining during his procedures.
Procedure
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Demographical information collected included name; date of birth; age at diagnosis; and
survival from diagnosis until death, or present if they were still alive. Patient identifying
information was used only for the purpose of collating information. Overall survival was
calculated from the diagnosis of glioblastoma, even if lower grade tumors were present
before this diagnosis. The prognostic factors we looked at individually as independent
variables were:
•

age (below 60 years, 60 years and above)

World Neurosurg. Author manuscript; available in PMC 2019 July 01.

Urhie et al.

Page 4

Author Manuscript

•

MGMT gene methylation status (positive, negative)

•

number of tumors at presentation (unifocal, multifocal)

•

surgical intervention (GTR, subtotal resection (STR), or biopsy)

•

completion of the Stupp protocol (full, incomplete, none)

Author Manuscript

The determination of GTR versus STR was made using Brainlab software to calculate tumor
volumes before and after surgery. Using this software, our criteria for GTR was a resection
of 98% or greater while STR was defined as being below 98% of the tumor volume, based
on one of the earlier papers that evaluated a threshold for a beneficial extent of resection and
found that removing ≥98% of the tumor had the greatest effect on increasing survival17. We
calculated survival due to the surgical intervention from the date of the initial resection/
biopsy. In cases where a biopsy preceded a resection by less than two months, we counted
the resection as the intervention as patients may have received a biopsy to assess the need for
– and extent of – resection. In all analyses that involve a surgical intervention, the
denominator we used was the total number of patients that received any surgical
intervention.
Due to clinical patient considerations, we considered a complete dose of radiation as being
54-63Gy. 13 patients died before chemoradiation was discussed or begun and were excluded
from our study. As radiation could start at various time points after a resection/biopsy and
last for various periods, the survival data for assessing the effect of completion of the Stupp
protocol were corrected to start from the mid-point of the course of concurrent
chemoradiation.
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In order to reflect the impact of the standard clinical management of glioblastoma, we then
sought to discover the survival impact of undergoing the standard course of treatment. For
this, we considered the surgical intervention they underwent and their completion of the
Stupp protocol. In doing so, we derived the following groups:
•

GTR with completion of the Stupp protocol

•

STR with completion of the Stupp protocol

•

Biopsy

Lastly, in order to assess how the impact of implementing the Stupp protocol in West
Virginia, we compared our results to those of Jubilirer (1996), taking care to compare the
groups in his study to equivalent groups in ours that reflect the standard of care.

Author Manuscript

Statistical analysis
With survival as an endpoint, we calculated median survival, with standard error (SE) and
95% confidence intervals (CI) using the formulas below, for the above prognostic factors.
The standard error formula was adjusted for the use of median values by multiplying by
1.253. A Moods test in XLSTAT (Addinsoft) with multiple pairwise comparisons set to give
exact p-values was used to evaluate for significance among the medians of the groups into
which the prognostic factors were divided. Pairwise testing was used as the groups under
each prognostic factor (or combination of) carry their own clinical weight. α was set at 0.05
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for all these conditions. Kaplan-Meier curves were also made in XLSTAT for the groups of
each prognostic factor. These curves were used to compare the number of patients alive after
1 year. We used a log rank test to evaluate for significance among the curves.
In comparing our date to that of Jubelirer’s, we calculated the percentage of people who had
undergone a specific intervention by setting the denominator to be the number of patients
that had received any surgical intervention (including a biopsy). Lastly, we calculated the
95% CI for the groups in our data that were equivalent to his.

CI lower limit
n 1.96 n
−
th ranked value
2
2
CI upper limit
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1+

n 1.96 n
+
th ranked value
2
2

Results
Age and survival

Author Manuscript

The majority of our patients were above 60 years old when initially diagnosed (Table 1) with
the median age at diagnosis in our patient population being 63.5 years (Table 2). Our patient
population had a median survival of 7 months (SE ± 1.3) with 18 people who had survived
longer than 36 months (long-term survivors), most of whom were under 60 years at the time
of diagnosis (see tables). The group of patients who were below 60 years at diagnosis had a
higher median survival of 14 months (SE ± 2.5; 95% CI: 11–18); the group of patients above
60 years at the time of diagnosis had a median survival of 4 months (SE ± 1.2; 95% CI: 3–5)
(Figure 1). A Moods test showed that these results were significantly different (p<0.0001).
The 1-year survival in the group of patients who were below 60 at the time of diagnosis was
55% while that in the group of patients above 60 at the time of diagnosis was 21% (Figure
2). A log-rank test showed that the survival distribution of these groups over time were
significantly different (p<0.0001).
Tumor characteristics and survival
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The molecular marker tested most frequently was MGMT, albeit tested in less than 50% of
initial cases – the gene was found to be methylated (MGMT+) in 37% of patients tested. We
found that the MGMT+ group had a median survival of 14 months (SE ± 3.0; 95% CI: 8–22)
while that of the MGMT- group was 7 months (SE ± 2.4; 95% CI: 4–11) (Figure 1). A
Moods test showed that these values were significantly different (p=0.021). The MGMT+
group had a 1-year survival of 49% while the MGMT- group had a 1-year survival of 29%
(Figure 2). A log-rank test showed that the survival distribution of these groups over time
were not significantly different (p=0.069).
Most of our patients had unifocal tumors at presentation, mostly in the frontal lobe. Most
multifocal tumors also involved the frontal lobe. The groups with unifocal tumors at
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presentation had a median survival of 8.5 months (SE ± 1.5; 95% CI: 6–10) while this was 4
months (SE ± 2.4; 95% CI: 2–9) in the group with multifocal tumors (Figure 1). A Mood’s
test showed that these values were significantly different (p=0.010). The group with a
unifocal tumor at presentation had a 1-year survival of 36% while the group with multifocal
tumors showed a 1-year survival of 24% (Figure 2). A log-rank test showed that the survival
distribution of these groups over time were significantly different (p=0.023).
Individual interventions and survival
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Most of our patients received a resection at WVUH as part of their treatment, with 41
patients having both a biopsy and a resection – in such cases, the biopsy was used to
determine a diagnosis and/or assess the need for resection. Of all patients that had a
resection, 50 were scheduled for a re-resection either due to incomplete resection or
recurrence (Table 1). Here, we only include results for those patients whose pre- and postoperative scans we had, from which we were able to assess an accurate extent of resection.
The group that received GTR had the longest median survival of 15 months (SE ± 6.6; 95%
CI: 12–24). The group that received STR had a median survival of 10 months (SE ± 7.8;
95% CI: 3–15) while the group that received a biopsy had a median survival of 3 months
(SE ± 0.8; 95% CI: 2–4) (Figure 1). A Moods test showed a significant difference in survival
between only the groups that received GTR and biopsy (p<0.0001). The group that received
GTR had the highest 1-year survival of 64%. The 1-year survival with the group that
received STR was 41%, while that for the group with a biopsy was 10% (Figure 2). A logrank test showed that the survival distribution of these groups over time were significantly
different (p<0.0001).
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Among the patients for whom we had definitive information, most of those who underwent
radiation completed treatment as per the Stupp protocol. The group that completed the Stupp
protocol had a median survival of 16 months (SE ± 3.3; 95% CI: 13–20), the group that did
not undergo this treatment had a median survival of 3 months (SE ± 2.4; 95% CI: 1–5),
while the group that did not complete this treatment had a median survival of 2 months (SE
± 0.6; 95% CI: 1–3) (Figure 1). A Moods test showed that the result for the group that
completed the Stupp protocol differed significantly from both the group that did not undergo
(p=0.0004) or not complete this treatment (p<0.0001). The group that completed the Stupp
protocol had a 1-year survival of 66%. The group that did not undergo this treatment had a
1-year survival of 12%, while the group that did not complete this treatment had a 1-year
survival of 0% (Figure 2). A log-rank test showed that the survival distribution of these
groups over time were significantly different (p<0.0001).

Author Manuscript

Treatment course and survival
The group that had received GTR with completion of the Stupp protocol showed the greatest
median survival of 23.5 months (SE ± 7.1; 95% CI: 13–34) and 1-year survival of 87%. The
group that received STR with completion of the Stupp protocol had a median survival of 14
months (SE and 95% CI could not be calculated) with a 1-year survival of 63% (see figures).
A Moods test showed a significant difference in median survival between those that received
GTR and completed the Stupp protocol and those that received a biopsy (p<0.0001). A log-
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rank test showed that the survival distribution of these groups over time were significantly
different (p<0.0001).
Comparison to previous West Virginia study

Author Manuscript

We compared the treatment groups in the Jubilirer 1996 study to equivalent groups in ours.
Overall median survival, survival with STR, and survival with STR and radiation therapy
(RT; for which the equivalent in our study is completion of the Stupp protocol) were similar
between our studies. The percentage of patients receiving GTR alone, GTR and RT, STR
alone, and STR and RT were all decreased in our study. Lastly, the survival with GTR,
survival with GTR and RT, percentage receiving biopsy, percentage receiving RT, and 1st
and 2nd year survival were all increased in our study (Table 2). For the purposes of this table,
biopsies were only considered when comparing surgical interventions and were not part of
the comparison for the treatment courses. Survival with the treatment courses and percentage
receiving RT are given as a percentage of all patients that received resection.

Discussion
As age, MGMT gene methylation, tumor burden, extent of resection, and the Stupp protocol
have all been linked to survival in other studies, we performed this study to determine the
impact these prognostic factors have on our patient population as a way of assessing the
outcome of glioblastoma care provided by our institution within the context of being in a
state with poor health metrics and outcomes. Our principal finding was that glioblastoma
survival is influenced by patient, tumor, and treatment factors.

Author Manuscript

We found that an increased age at the time of diagnosis corresponded with decreased
survival (see figures). The low overall median survival of our patient population may be
explained by the fact that the majority of them were above 60 years at the time of diagnosis
(Table 1). Our finding of a low median and 1-year survival in the elderly group corroborates
other studies which also find a low median survival of 4–6 months in this population,
sometimes even with standard treatment14,21. In such cases, attention shifts towards
maintaining a good quality of life. It is, however, noted that these patients still face many
morbidities13.

Author Manuscript

As it determines the patient’s responsiveness to treatment with TMZ, we surveyed the
survival of patients with MGMT methylation. Our findings that MGMT methylation
increased survival (see figures) are in line with other studies that have found MGMT
methylation to be a strong prognostic factor10,15 although this is not universal20. Other
markers such as epidermal growth factor receptor6, alkylpurine-DNA-N-glycosylase 1,
isocitrate dehydrogenase 124, alpha thalassemia/mental retardation syndrome X-linked 7,
and p5323 may be tested and have independent and dependent prognostic implications, but
none of these helps determine a treatment modality.
Since multifocality may influence the risk of undergoing GTR, we looked at the survival of
patients with using this variable. Most (81%) of patients presented with unifocal tumors.
When patients presented with multifocal tumors, the approach used was to target the
resection to the larger tumors evident on imaging and attempt to remove easily accessible
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nodules within their vicinity. We found an increased median survival in patients with
unifocal tumors on presentation (see figures), which may be due to anatomic difficulties in
achieving GTR or due to a different biological behavior of these tumors.
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Resection clearly improved survival over biopsy (see figures). When performed as the sole
intervention, a biopsy was done when the patient was elderly and likely to face further
morbidity as a result of the surgery or when the tumor was in a deep location that made
resection dangerous. For our analyses, we considered any resection ≥ 98% to be GTR. GTR
significantly increases survival over STR as there is a decreased chance of recurrence;
indeed, most of our recurrences were in patients who had initial subtotal resections.
Unfortunately, GTR is not possible when the chance of injury to eloquent areas is high. Our
findings support many studies that have found GTR to be a strong prognostic factor18,22.
These studies also suggest that resection of the surrounding FLAIR (fluid attenuated
infusion recovery) signal may also be beneficial.
Completion of the recommended Stupp protocol improved survival (see figures). It is
important to note the Stupp protocol calls for the use of concurrent TMZ with 54-63Gy
radiation AND six cycles of post-radiation TMZ; the group that did not complete their
therapy consisted of those who did not adhere to both requirements. Radiation doses
prescribed by the neuro-onclogist depended on age and need for aggressive treatment.
Reasons for not completing the Stupp protocol or forgoing it altogether include a decision to
go into palliative care, lack of insurance, worsening morbidity, and an assessment by the
neuro-oncologist that radiation would provide no benefit. Again, here, treatment is focused
on enhancing quality of life.
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In agreement with the literature, the highest survival in our patient population was seen in
the group that received GTR and adhered to the Stupp protocol (see figures). Predictably, the
group that underwent STR and adhered to the Stupp protocol had a lower survival. Both
figures suggest that GTR and the Stupp protocol greatly augment each other.
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Our comparison with Julbilirer’s study16 shows that the standard management for
glioblastoma – GTR with completion of the Stupp protocol – has indeed improved median
survival in West Virginia (Table 2). This comparison further highlights that overall median
survival has indeed not increased, even with the implementation of the Stupp protocol, use
of new modalities, research, and advents in technology. As the interventions involving GTR
resulted in increased survival in our patients, the lack of an increased overall survival may be
due to the large number of biopsies we perform as the sole intervention. A possible reason
for the prevalence of biopsies among our patients may be a reasonable reluctance to subject
the elderly and those that present with low Karnofsky Performance Scale (KPS) scores to
resection, a trend that is also present at other institutions21. However, a study by Marina et al
found that conventional therapy19 – or at least STR28 – does improve survival and functional
outcomes in elderly patients.
We discovered that the three factors that yielded a median survival at or above the reported
value of 14.6 months were receiving GTR (regardless of post-surgical interventions),
adhering to the Stupp protocol (regardless of surgical intervention) and undergoing a
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treatment course of GTR followed by the Stupp protocol. Our results highlight the fact that
multiple conditions/interventions differently influence the survival of a patient with
glioblastoma and that survival has to be considered by the neurosurgeon using such a
multifactorial stance. Currently, with a median survival of 7 months, we acknowledge that
there are deficiencies in care (patient and disease factors notwithstanding) even with
standard interventions being available, which may well stem from outside the hospital
setting. We may increase the survival in our patient population by having discussions
through which patients understand the disease process and treatments available and in which
we advocate (when safe) for the best treatment course – GTR followed by full concurrent
chemoradiation and post-radiation TMZ. We will also work with patients and other members
of the healthcare team to ensure both that patients have access to – and follow up with –
appropriate and timely aspects of standard care.

Author Manuscript
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Unique challenges that patients in West Virginia and the rest of rural Appalachia face in
attaining optimal care for glioblastoma may include low health literacy4, sparse distribution
of tertiary care centers, resigned attitudes to terminal illness, and lack of social and family
support. In a future study, we will identify sociodemographic factors (cultural views,
income, education, insurance et al) which negatively affect survival with glioblastoma
among patients in West Virginia. Some limitations of this study stem from its retrospective
nature that covers patients over a period of 7 years. Firstly, we have added many treatment
tools since the earliest diagnosis were recorded, which was in 2009. We also have also not
accounted for advances in training and management protocols and changes in personnel that
have occurred since then. Secondly, our molecular marker analysis is limited to MGMT as
other markers were not routinely tested for in the earlier part of this study; until the WHO
2016 classification made isocitrate dehydrogenase testing routine, we only ordered this test
when necessary for diagnosis. We now order IDH and MGMT testing routinely, as well as
newer clinically relevant markers when appropriate, but the number of these newer markers
is too low for to allow analysis.
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MGMT

O6-methylguanine methyltransferase

GTR

gross total resection

TMZ

temozolomide

CAMC

Charleston Area Medical Center

WVUH

West Virginia University Hospital

STR

subtotal resection

SE

standard error of the median
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CI

confidence interval

FLAIR

fluid attenuated inversion recovery
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Highlights
1.

An age of diagnosis under 60 years, having the MGMT gene methylated,
having a unifocal tumor, receiving gross total resection (GTR), adhering to
the Stupp protocol, and undergoing a treatment course of GTR followed by
the Stupp protocol significantly increased survival among patients in West
Virginia

2.

Despite much advances in glioblastoma management, median survival of
patients in West Virginia has not increased since 1996. However, all
interventions involving GTR have significantly enhanced survival since then.
The fact that median survival has not increased warrants further investigation.
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Figure 1.
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Bar graphs showing median survival in months, with SE, according to prognostic indicators
of survival: a) age at diagnosis; b) MGMT methylation status; c) number of lesions; d)
surgical intervention; e) completion of the Stupp protocol; f) treatment course
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Figure 2.
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Kaplan Meier curves of cumulative probability of survival over time according to: a) age at
diagnosis; b) MGMT methylation status; c) number of lesions; d) surgical intervention; e)
completion of the Stupp protocol; f) treatment course

Author Manuscript
World Neurosurg. Author manuscript; available in PMC 2019 July 01.

Urhie et al.

Page 15

Table 1

Author Manuscript

Demographic, treatment, and survival information of patients treated for glioblastoma. CRT = chemoradiation,
GTR = gross total resection, STR = subtotal resection
Number of patients

Percentage of patients

Number of long- term survivors

147

60.5

96

39.5

98

40.3

14

145

59.7

4

Biopsy alone

70

52.6

0

STR

27

20.3

2

36

27.1

7

50/125

40.0

Gender
Male
Female
Age at diagnosis
20–59
≥60
Surgical technique useda

Author Manuscript

GTR
Re-resection

Completion of the Stupp protocolb
Full

67

60.4

10

Incomplete

26

23.4

0

None

18

16.2

0

Survival (m)
<1

Author Manuscript

17

7.0

1–12

143

58.8

13–24

46

18.9

25–36

19

7.8

6

2.5

12

4.9

37–48
>48

a

some patients did not have post-operative imaging and thus could not be definitely classified as having received STR or GTR

b

adherence to the Stupp protocol could not be determined for some patients treated at other institutions
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Summary of interventions and outcomes between our current study and Jubilirer’s 1996 study at CAMC. “RT”
should be taken to mean “Stupp protocol” in the context of WVUH. CAMC: Charleston Area Medical Center,
CI: Confidence interval, GTR: Gross total resection, RT: radiation therapy, STR: Subtotal resection, WVUH:
West Virginia University Hospitals

Number of patients
Median age at diagnosis (range)
Percentage of females
Overall median survival (95% CI)

WVUH

CAMC

243

138

63 (20–88)

59 (21–87)

39.5

42

7 (6–10)

7

27.1

29

15 (10–25)

4 (2–6)

11.2

23.9

23.5 (12–37)

12 (10–13)

20.3

26.1

10 (3–15)

3 (1–7)

6.0

18.8

14 (3–16)

10 (7–14)

52.6

2.2

73

42.7

1-year survival (%)

36.6

29

2-year survival (%)

15.4

3

Percentage receiving GTR
Survival with GTR (95% CI)
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Percentage receiving GTR and RT
Survival with GTR and RT (95% CI)
Percentage receiving STR
Survival with STR (95% CI)
Percentage receiving STR and RT
Survival with STR and RT (95% CI)
Percentage receiving biopsy
Percentage receiving RT
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